Indoleamine 2,3-dioxygenase-1 (IDO) is an immune regulatory enzyme expressed by most human tumors. IDO levels in tumor cells correlate with increased metastasis and poor patient outcome and IDO is linked to tumor cell resistance to immunotherapy, radiation therapy, and chemotherapy. Knowledge of tumor cell-autonomous effects of IDO, independent of its well-known role in regulating and suppressing anti-tumor immune responses, is limited. Clonal populations of A549 human lung adenocarcinoma cells stably transfected with anti-IDO shRNA or scrambled control shRNA were used to study IDO effects on drug sensitivity and resistance. IFNγ was used to induce IDO in those cells. We show, for the first time, that IDO mediates human tumor cell resistance to the candidate anticancer drugs FK866 (an NAD+ inhibitor), methoxyamine (MX, a base excision repair [BER] inhibitor) and approved anticancer drugs pemetrexed (a folate anti-metabolite) and gemcitabine (a nucleoside analogue), and combined treatment with pemetrexed and MX, in the absence of immune cells. Concurrent knockdown of IDO and thymidylate synthase (TS, a key rate-limiting enzyme in DNA synthesis and repair) sensitizes human lung cancer cells to pemetrexed and 5FUdR to a greater degree than knockdown of either target alone. We conclude that BER in IDO-expressing A549 cells plays a major role in mediating resistance to a range of approved and candidate anticancer drugs. IDO inhibitors are undergoing clinical trials primarily to improve antitumor immune responses. We show that targeting IDO alone or in combination with TS is a potentially valuable therapeutic strategy for cancer treatment, independent of immune activity and in combination with conventional chemotherapy.
IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells
S. Maleki Vareki,Di Chen,C. Di Cresce,P. Ferguson,R. Figueredo,Macarena Pampillo,M. Rytelewski,M. Vincent,W. Min,Xiufen Zheng,J. Koropatnick
Published 2015 in PLoS ONE
ABSTRACT
PUBLICATION RECORD
- Publication year
2015
- Venue
PLoS ONE
- Publication date
2015-11-18
- Fields of study
Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
CONCEPTS
- 5fudr
A fluorinated deoxyribonucleoside used as a chemotherapy-related test compound in the knockdown experiments.
Aliases: 5-fluoro-2'-deoxyuridine, 5-fluorodeoxyuridine
- a549 human lung adenocarcinoma cells
A human lung adenocarcinoma cell line used as the tumor-cell model in the experiments.
Aliases: A549 cells, A549
- base excision repair (ber)
A DNA repair pathway implicated in the drug-resistance phenotype observed in the IDO-expressing cells.
Aliases: BER, base excision repair
- conventional chemotherapy
Standard anticancer drug treatment context referenced in the therapeutic conclusion.
Aliases: chemotherapy
- fk866
A small-molecule anticancer candidate described in the abstract as an NAD+ inhibitor.
Aliases: NAD+ inhibitor FK866
- gemcitabine
A nucleoside analogue anticancer drug tested in the lung cancer cell assays.
- indoleamine 2,3-dioxygenase-1 (ido)
An immune-regulatory enzyme expressed in the A549 lung cancer cell model used in the experiments.
Aliases: IDO, indoleamine 2,3-dioxygenase-1
- methoxyamine (mx)
A small-molecule base excision repair inhibitor used in combination and single-agent treatments.
Aliases: methoxyamine, MX
- pemetrexed
A folate anti-metabolite anticancer drug tested in the lung cancer cell assays.
- thymidylate synthase (ts)
A key rate-limiting enzyme in DNA synthesis and repair that was targeted together with IDO.
Aliases: TS, thymidylate synthase
REFERENCES
Showing 1-48 of 48 references · Page 1 of 1
CITED BY
Showing 1-38 of 38 citing papers · Page 1 of 1